PARP1 and lung carcinoma: A combination of BET and PARP inhibition has demonstrated efficacy in inhibiting tumorigenesis in preclinical models of numerous malignancies, including pancreatic, breast, ovarian, prostate, and lung cancers [13, 15, 17, 22].